For research use only. Not for therapeutic Use.
Somatostatin receptor agonist and also a 5-HT agonist; FK960 stimulates both serotonin and somatostatin production as a cognitive enhancer. However, its development for Alzheimer’s disease (AD) was terminated in 2003
| Catalog Number | I005972 |
| CAS Number | 133920-70-4 |
| Molecular Formula | C13H16FN3O2 |
| Purity | ≥95% |
| IUPAC Name | N-(4-acetylpiperazin-1-yl)-4-fluorobenzamide |
| InChI | InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19) |
| SMILES | CC(=O)N1CCN(CC1)NC(=O)C2=CC=C(C=C2)F |
| Reference | A Graul et al. FK-960, Congnition Enhancer. Drug. Fut. 1997, 22(8), 830-832.
N Matsuoka and TG Ainer. FK960 [N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate], a Novel Potential Antidementia Drug, Improves Visual Recognition Memory in Rhesus Monkeys… J. Pharmacol. Exp. Ther. 1997, 280(3), 1201-1209.
JP Hodgkiss and JS Kelly. Effect of FK960, a Putative Cognitive Enhancer, on Synaptic Transmission in CA1 Neurons of Rat Hippocampus. J. Pharmacol. Exp. Ther. 2001, 297(2), 620-628.
F Wang et al. Modulation of Ca2+Channel Currents by a Novel Antidementia Drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate (FK960) in Rat Hippocampal Neurons. J. Pharmacol. Exp. Ther. 2004, 308 (1), 120-126. |
